Seeking Alpha

Novavax, Inc. (NVAX)

  • Jun. 4, 2013, 7:52 AM
    Novavax (NVAX) makes a public offer to acquire all outstanding shares of Isconova, a Sweden-based company which makes vaccine adjuvants and has an impressive list of big pharma partners. The all-stock deal is worth~$29.6M. (PR)
    | Jun. 4, 2013, 7:52 AM | Comment!
Visit Seeking Alpha's
NVAX vs. ETF Alternatives
Company Description
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Sector: Healthcare
Industry: Biotechnology
Country: United States